| Literature DB >> 35632602 |
Jinwoo Kim1, Miyoung Cho2, Jongwon Lim1, Hyeseong Choi2, Suhee Hong1.
Abstract
Infectious hematopoietic necrosis virus (IHNV) is a pathogen that causes high rates of mortality in salmonid fishes. Therefore, an RNA-seq-based transcriptome analysis was performed in the head kidney of rainbow trout infected with a highly virulent IHNV strain to understand the pathogenesis of and defense strategies for IHNV infection in rainbow trout. The results showed that the numbers of DEGs were 618, 2626, and 774 (control vs. IHNV) on days 1, 3, and 5, respectively. Furthermore, the enrichment analysis of gene ontology (GO) annotations to classify DEGs showed that GO terms considerably associated with DEGs were gluconeogenesis, inflammatory response, and cell adhesion in the Biological Process (BP) category, apical plasma membrane, extracellular matrix (ECM) in the Cellular Component category, and transporter activity, integrin binding, and protein homodimerization activity in the Molecular Function category, on days 1, 3, and 5, respectively. Notably, GO terms in the BP category, including the negative regulation of type I interferon production and positive regulation of interleukin-1β secretion, were commonly identified at all time points. In the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, complement and coagulation cascades were commonly identified at all time points. Importantly, the widely recognized GO terms and KEGG pathways extensively linked to DEGs were related to energy metabolism on day 1, the immune response on day 3, and cell proliferation on day 5. Furthermore, protein-protein interaction networks and centrality analysis showed that the metabolism and signaling transduction pathways were majorly upregulated. Conclusively, the virulent IHNV infection drives pathogenesis by activating the metabolic energy pathway for energy use for viral replication, facilitating necrosis through autophagy, and causing a shutoff response of the host immune system through the downregulation of type I IFN at the initial stage of infection.Entities:
Keywords: IHNV; pathogenesis; rainbow trout; transcriptome
Mesh:
Year: 2022 PMID: 35632602 PMCID: PMC9143916 DOI: 10.3390/v14050859
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.818
Figure 1Cumulative percent mortality (CPM) of rainbow trout challenged by intraperitoneal injection with IHNV. Forty rainbow trout were divided into two groups and challenged with PBS or the IHNV RtCc0517c strain (104 PFU/fish). Mortality was recorded daily for 30 days.
Comparative analysis of DEGs between groups 1 and 2.
| Time | Group 1 | Group 2 | Number of Genes | ||
|---|---|---|---|---|---|
| Total a | Up b | Down c | |||
| 1 | Control | IHNV | 618 | 525 | 93 |
| 3 | Control | IHNV | 2626 | 1236 | 1390 |
| 5 | Control | IHNV | 774 | 482 | 292 |
a Total number of DEGs in groups 1 and 2. b Group 2 is more upregulated than group 1. c Group 2 is more downregulated than group 1.
GO terms commonly identified at all time points in IHNV-infected fish.
| Category | GO ID | GO Terms | Fold Enrichments | ||
|---|---|---|---|---|---|
| Day 1 | Day 3 | Day 5 | |||
| BP | GO:0032480 | Negative regulation of type I IFN production | 8.63 | 5.17 | 10.87 |
| GO:0048661 | Positive regulation of smooth muscle cell proliferation | 5.04 | 2.95 | 6.79 | |
| GO:0050718 | Positive regulation of IL-1β secretion | 9.81 | 4.03 | 7.41 | |
| GO:0051607 | Defense response to virus | 2.35 | 2.48 | 3.21 | |
| GO:0002576 | Platelet degranulation | 3.77 | 2.58 | 2.77 | |
| GO:0009615 | Response to virus | 2.75 | 2.72 | 4.45 | |
| GO:0010575 | Positive regulation of VEGF production | 6.40 | 3.28 | 6.04 | |
| CC | GO:0031093 | Platelet alpha granule lumen | 5.71 | 3.31 | 3.80 |
| GO:0016323 | Basolateral plasma membrane | 3.49 | 2.27 | 3.25 | |
| GO:0009925 | Basal plasma membrane | 7.48 | 2.65 | 5.57 | |
IFN, interferon; IL, interleukin; VEGF, vascular endothelial growth factor.
Top GO terms identified at each point in IHNV-infected fish.
| Category | Day 1 | Day 3 | Day 5 | |||
|---|---|---|---|---|---|---|
| GO Terms | F * | GO Terms | F * | GO Terms | F * | |
| BP | Gluconeogenesis | 10 | Inflammatory response | 2 | Cell adhesion | 3 |
| Transmembrane transport | 3 | ECM organization | 3 | Negative regulation of type I IFN production | 11 | |
| Cellular response to hypoxia | 4 | Cell adhesion | 2 | ECM organization | 4 | |
| Transport | 2 | Leukocyte migration | 3 | Positive regulation of smooth muscle cell proliferation | 7 | |
| Sodium ion transport | 5 | Defense response to virus | 2 | Response to virus | 4 | |
| Negative regulation of type I IFN production | 9 | Negative regulation of type I IFN production | 5 | Positive regulation of IFNα production | 17 | |
| Anion transmembrane transport | 9 | Cytokine-mediated signaling pathway | 3 | ERBB2 signaling pathway | 8 | |
| Spinal cord development | 9 | Cellular response to mechanical stimulus | 3 | Positive regulation of IFNβ production | 9 | |
| Response to organic cyclic compound | 6 | Response to virus | 3 | Defense response to virus | 3 | |
| Cellular response to cAMP | 6 | TGFβ receptor signaling pathway | 3 | Negative regulation of endopeptidase activity | 4 | |
| Regulation of intracellular pH | 7 | Positive regulation of ERK1 and ERK2 cascade | 2 | Innate immune response | 2 | |
| Positive regulation of IL-1β secretion | 10 | Cell–matrix adhesion | 3 | C21-steroid hormone biosynthetic process | 18 | |
| Chloride transport | 6 | TNF-mediated signaling pathway | 3 | Glucocorticoid biosynthetic process | 18 | |
| Innate immune response | 2 | Platelet degranulation | 3 | Response to drug | 2 | |
| Positive regulation of smooth muscle cell proliferation | 5 | Peptidyl-tyrosine phosphorylation | 2 | Sterol metabolic process | 10 | |
| CC | Apical plasma membrane | 4 | ECM | 3 | ECM | 4 |
| Brush border membrane | 7 | Cell surface | 2 | Extracellular space | 2 | |
| Basolateral plasma membrane | 3 | Extracellular vesicle | 4 | Basement membrane | 6 | |
| Platelet alpha granule lumen | 6 | External side of plasma membrane | 2 | Cell surface | 2 | |
| Stereocilium | 8 | Proteinaceous ECM | 2 | Proteinaceous ECM | 3 | |
| MF | Transporter activity | 3 | Integrin binding | 3 | Protein homodimerization activity | 2 |
| Pyridoxal phosphate binding | 6 | Fibronectin binding | 6 | NAD+ADP-ribosyltransferase activity | 9 | |
| Enzyme binding | 2 | Collagen binding | 4 | Integrin binding | 4 | |
| Transaminase activity | 13 | Receptor activity | 2 | ECM structural constituent | 5 | |
| Receptor binding | 2 | Laminin binding | 5 | Phosphatidylserine binding | 7 | |
The order of the list is itemized from the lowest p-value. * F, fold enrichment.
KEGG pathways commonly identified in IHNV-infected fish.
| Category | Pathway ID | Pathway Terms | Fold Enrichments | ||
|---|---|---|---|---|---|
| Day 1 | Day 3 | Day 5 | |||
| Immune system | hsa04610 | Complement and coagulation cascades | 3.77 | 2.47 | 3.47 |
| Amino acid metabolism | hsa00260 | Glycine, serine, and threonine metabolism | 5.72 | 2.19 | NI |
| Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 8.08 | 2.88 | NI |
| Membrane transport | hsa02010 | ABC transporters | 4.23 | NI | 4.67 |
| Infectious disease | hsa05144 | Malaria | NI | 2.51 | 4.89 |
| hsa05162 | Measles | NI | 2.07 | 2.57 | |
| Signal transduction | hsa04514 | Cell adhesion molecules | NI | 2.40 | 3.13 |
NI, not identified or ignored, as p-value > 0.05 or fold enrichments <2.0.
KEGG pathways uniquely identified at each time point in IHNV-infected fish.
| Time | Pathway ID | Pathway Terms | No. of DEGs | F * |
|---|---|---|---|---|
| Day 1 | hsa04976 | Bile secretion | 10 | 5.39 |
| hsa03320 | PPAR signaling pathway | 9 | 4.99 | |
| hsa01200 | Carbon metabolism | 11 | 3.62 | |
| hsa01130 | Biosynthesis of antibiotics | 15 | 2.63 | |
| hsa00340 | Histidine metabolism | 5 | 8.45 | |
| hsa01230 | Biosynthesis of amino acids | 8 | 4.13 | |
| hsa00630 | Glyoxylate and dicarboxylate metabolism | 5 | 6.89 | |
| hsa00330 | Arginine and proline metabolism | 6 | 4.46 | |
| hsa04920 | Adipocytokine signaling pathway | 7 | 3.72 | |
| hsa04152 | AMPK signaling pathway | 9 | 2.72 | |
| hsa04978 | Mineral absorption | 5 | 4.23 | |
| hsa00010 | Glycolysis/Gluconeogenesis | 6 | 3.33 | |
| hsa00410 | b-Alanine metabolism | 4 | 4.8 | |
| Day 3 | hsa04060 | Cytokine-cytokine receptor interaction | 52 | 2.03 |
| hsa04514 | Cell adhesion molecules (CAMs) | 36 | 2.4 | |
| hsa04380 | Osteoclast differentiation | 34 | 2.46 | |
| hsa04064 | NF-kappa B signaling pathway | 23 | 2.5 | |
| hsa04620 | Toll-like receptor signaling pathway | 26 | 2.32 | |
| hsa05160 | Hepatitis C | 30 | 2.14 | |
| hsa04668 | TNF signaling pathway | 24 | 2.13 | |
| hsa05140 | Leishmaniasis | 17 | 2.27 | |
| hsa00250 | Alanine, aspartate, and glutamate metabolism | 11 | 2.98 | |
| hsa05144 | Malaria | 13 | 2.51 | |
| hsa04622 | RIG-I-like receptor signaling pathway | 16 | 2.17 | |
| hsa05410 | Hypertrophic cardiomyopathy (HCM) | 17 | 2.07 | |
| hsa04672 | Intestinal immune network for IgA production | 12 | 2.42 | |
| hsa04621 | NOD-like receptor signaling pathway | 13 | 2.2 | |
| hsa00220 | Arginine biosynthesis | 7 | 3.32 | |
| hsa04623 | Cytosolic DNA-sensing pathway | 14 | 2.07 | |
| hsa05321 | Inflammatory bowel disease (IBD) | 14 | 2.07 | |
| hsa04930 | Type II diabetes mellitus | 11 | 2.17 | |
| hsa04964 | Proximal tubule bicarbonate reclamation | 7 | 2.88 | |
| hsa04710 | Circadian rhythm | 8 | 2.45 | |
| hsa00260 | Glycine, serine, and threonine metabolism | 9 | 2.19 | |
| Day 5 | hsa04913 | Ovarian steroidogenesis | 9 | 6.29 |
| hsa05164 | Influenza A | 16 | 3.15 | |
| hsa04514 | Cell adhesion molecules (CAMs) | 13 | 3.13 | |
| hsa00140 | Steroid hormone biosynthesis | 8 | 4.72 | |
| hsa05144 | Malaria | 7 | 4.89 | |
| hsa05168 | Herpes simplex infection | 13 | 2.43 | |
| hsa05161 | Hepatitis B | 10 | 2.36 | |
| hsa04512 | ECM–receptor interaction | 7 | 2.75 | |
| hsa04974 | Protein digestion and absorption | 7 | 2.72 | |
| hsa00760 | Nicotinate and nicotinamide metabolism | 4 | 4.72 | |
| hsa04622 | RIG-I-like receptor signaling pathway | 6 | 2.93 | |
| hsa05140 | Leishmaniasis | 6 | 3.17 |
The order of the list is from the lowest p-value (<0.05). * F, fold enrichment.
Figure 2Protein–protein interaction network analysis of DEGs. Control vs. IHNV. The STRING database analyzed the protein–protein interaction network based on the proteins matching the selected DEGs on days 1 (A), 3 (B), and 5 (C). The protein interaction relationship of DEGs existing in the string database was selected for the network formation. The red color indicates upregulated genes; the blue color indicates downregulated genes. Node sizes are proportional to p-values.
The top ten nodes of centrality analysis of the PPI network in the IHNV injected group.
| Time (Day) | Category * | Accession ID | Node Name | Closeness Centrality ** | Betweenness Centrality *** |
|---|---|---|---|---|---|
| 1 | 12, 13, 14 | ENSP00000229239 | GAPDH | 0.637 | 0.213 |
| 4, 11, 13, 14, 15 | ENSP00000319814 | PCK1 | 0.586 | 0.051 | |
| 12, 13, 14, 16 | ENSP00000302620 | AGXT | 0.574 | 0.074 | |
| 11 | ENSP00000295834 | FABP1 | 0.563 | 0.064 | |
| 4 | ENSP00000312987 | HNF4A | 0.558 | 0.053 | |
| 12, 13, 14 | ENSP00000363988 | ALDOB | 0.542 | 0.021 | |
| 4, 11, 13, 14, 15 | ENSP00000216780 | PCK2 | 0.532 | 0.016 | |
| 4, 11, 14 | ENSP00000253801 | G6PC | 0.523 | 0.035 | |
| 16 | ENSP00000291670 | FTCD | 0.523 | 0.037 | |
| 17 | ENSP00000266088 | SLC5A1 | 0.504 | 0.064 | |
| 1, 2, 3, 4, 5, 7, 8 | ENSP00000398698 | TNF | 0.611 | 0.141 | |
| 3 | 1, 2, 3, 4, 5, 7, 8 | ENSP00000398698 | TNF | 0.611 | 0.141 |
| 1, 2, 3, 4, 5, 7 | ENSP00000263341 | IL1B | 0.558 | 0.119 | |
| 1, 2, 4, 5 | ENSP00000451828 | AKT1 | 0.553 | 0.094 | |
| 1, 2, 5, 7 | ENSP00000354394 | STAT1 | 0.546 | 0.054 | |
| 1, 2, 7 | ENSP00000260010 | TLR2 | 0.543 | 0.041 | |
| 1 | ENSP00000275493 | EGFR | 0.524 | 0.048 | |
| 1, 2, 3, 4 | ENSP00000361359 | CD40 | 0.520 | 0.021 | |
| 1, 2, 4, 5, 7 | ENSP00000360266 | JUN | 0.519 | 0.047 | |
| 1, 3, 4 | ENSP00000294728 | VCAM1 | 0.512 | 0.030 | |
| 1, 2 | ENSP00000370034 | TLR7 | 0.508 | 0.016 | |
| 5 | 1 | ENSP00000361405 | MMP9 | 0.636 | 0.107 |
| 1 | ENSP00000360266 | JUN | 0.631 | 0.156 | |
| 1 | ENSP00000263341 | IL1B | 0.614 | 0.083 | |
| 11 | ENSP00000302665 | IGF1 | 0.603 | 0.101 | |
| 1 | ENSP00000354394 | STAT1 | 0.565 | 0.029 | |
| 1, 2 | ENSP00000245907 | C3 | 0.547 | 0.050 | |
| 11, 18 | ENSP00000478561 | CYP1B1 | 0.538 | 0.056 | |
| 11 | ENSP00000261693 | SCARB1 | 0.530 | 0.044 | |
| 1 | ENSP00000243077 | LRP1 | 0.530 | 0.010 | |
| 1, 3 | ENSP00000355751 | THBS2 | 0.530 | 0.027 |
* Categories of the PPI network showing a node’s involvement are represented by numbers: 1. Infectious disease, 2. The immune system, 3. Signaling molecules and interaction, 4. Signal transduction, 5. Development and regeneration, 6. Folding, sorting, and degradation, 7. Immune disease, 8. Endocrine and metabolic disease, 9. Cancer: overview, 10. Cellular community, 11. Endocrine system, 12. Global and overview maps, 13. Metabolism of terpenoids and polyketides, 14. Carbohydrate metabolism, 15. Excretory system, 16. Amino acid metabolism, 17. Digestive system, 18. Lipid metabolism. ** Closeness Centrality: Closeness coefficient shows the distance between a node and other nodes in the network. If very short, this indicates that the point is the center of the whole network. The larger the value, the closer the node is to the center of the network. *** Betweenness Centrality: Median Centrality reflects the role of a node in connection with other nodes. The larger the value, the more important the node is in maintaining the close connection of the whole network.
Figure 3Presentation of putative metabolism-related pathways on days 1, 3, and 5 in the IHNV-infected group. DEGs regulated by the IHNV infection are shown in red (upregulated) or blue (downregulated). The box is divided into three spaces, indicating the up- and downregulated genes on days 1, 3, and 5. The black arrows show the activation and regulatory responses of downstream pathways.
Figure 4Presentation of putative immune pathways on days 1, 3, and 5 in the IHNV-infected group. DEGs regulated by the IHNV are shown in red (upregulated) or blue (downregulated). The box is divided into three spaces, indicating the up- and downregulated genes on days 1, 3, and 5. The black arrows show the activation and regulatory responses of downstream pathways.
Figure 5Expression level of 12 randomly selected genes validated by Q-PCR. The EF-1α gene was used as an internal control, and each gene’s relative quantity of gene expression (fold change) was calculated comparatively. The asterisks indicate the level of significance based on an unpaired t-test (*, p < 0.05; **, p < 0.00; N = 8). IL-1β, interleukin-1beta; TNFα, tumor necrosis factor-alpha; IFN2, Type I IFN 2; IL-8, interleukin-8; MT-ATP8, ATP synthase protein 8; COX2, cytochrome c oxidase subunit 2; IRF9, IFN regulatory factor 9; RAC1, Ras-related C3 botulinum toxin substrate 1; PTK2, protein kinase domain-containing protein; TP53, cellular tumor antigen p53; IL-6, Interleukin-6; IL-18, Interleukin-18.